CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Program Title

Bipolar Disorder: Maximizing Outcomes and Minimizing Costs: Diagnostic Challenges and Cost Implications
Release Date: November-01-05
Credit Expiration Date: December-31-06


Martha Sajatovic, MD
Associate Professor Department of Psychiatry
Case Western Reserve University School of Medicine
Cleveland, OH

William Glazer, MD
Associate Clinical Professor of Psychiatry
Harvard Medical School
Boston, MA
President, Glazer Medical Solutions
Menemsha, MA

Credit Hours



Online Presentation

Program Description

This is the first program in a two-part series based on live audioconference presentations.

Bipolar disorder (BPD) is a serious health management issue that is associated with significant patient impairment and high direct and indirect costs. Much of the burden of BPD is associated with misdiagnosis or underdiagnosis of the disorder. This often occurs due to the dynamic nature and presentation of the disease as well as potential communication difficulty with patients. Patients often need to see several professionals prior to receiving an accurate diagnosis, which often results in a significantly delayed diagnosis. Early and accurate diagnosis may improve patient outcomes and decrease attendant health care costs. This activity provides epidemiological and financial background on the disorder, with recommendations for improving diagnostic outcomes.

Program Developer/Facilitator


Target Audience

Managed Care Medical Directors, Pharmacy Directors, Physicians, and Pharmacists.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss the pharmacoeconomics of bipolar disorder
  2. Describe how and why bipolar disorder is under- and misdiagnosed
  3. Evaluate strategies to better enable treatment providers (such as PCPs and psychiatrists) to improve diagnosis of bipolar disorder in managed care settings


AKH Inc. and its shareholders have no significant financial relationships with the manufacturers of medical or pharmaceutical products, nor with the providers of non-educational medical services. It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with the commercial companies whose products or devices may be mentioned in the monograph or with the commercial supporter of this continuing education activity. The information is for participant information only; it is not assumed that these relationships will have a negative impact on the content of the activity.

Martha Sajatovic, MD discloses that she is on speakers bureaus of AstraZeneca, GlaxoSmithKline, and Pfizer Inc, is a consultant for AstraZeneca and GlaxoSmithKline, serves on advisory committees for Bristol-Myers Squibb Company and AstraZeneca, and has received research support from Bristol-Myers Squibb Company and Abbott Laboratories.

William M. Glazer, MD discloses that he is on advisory committees of Eli Lilly and Company, AstraZeneca, Abbott Laboratories and Pfizer Inc. He is also president of ReliaLAB Inc.

This educational activity may contain discussion of published and/or investigational uses of agents for the treatment of bipolar disorder. Some uses of these agents have not been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

CME: This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates each of these educational activities for a maximum of 1 category 1 credit each toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

CPE: AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity has been assigned the Universal Program Number 077-999-05-034-H04 and is acceptable for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE-approved providers.

Participants must submit an evaluation and complete a post-test with a score of 70% or better to receive credit.

Commercial Support Statements

This activity is supported by an educational grant from AstraZeneca.


  1. Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  2. The next screen will permit you to check for or download the Flash player required to run this program.
  3. Clicking on "start the program" on this screen will bring you to instructions to turn off pop-up blockers and allow you to begin the program presentation which will take approximately 60 minutes to complete.
  4. Upon completion of the program, click on the post-test button to register and access the post-test and program evaluation.
  5. Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE certificate.

Certificate Fee



None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu